Humana (NYSE: HUM) recently received a number of ratings updates from brokerages and research firms:

  • 11/8/2018 – Humana had its price target raised by analysts at Royal Bank of Canada from $318.00 to $349.00. They now have a “sector perform” rating on the stock.
  • 11/8/2018 – Humana had its price target raised by analysts at Credit Suisse Group AG from $370.00 to $390.00. They now have an “outperform” rating on the stock.
  • 11/8/2018 – Humana had its price target raised by analysts at med from $350.00 to $373.00. They now have an “outperform” rating on the stock.
  • 11/8/2018 – Humana had its price target raised by analysts at Morgan Stanley from $400.00 to $418.00. They now have a “buy” rating on the stock.
  • 11/8/2018 – Humana was given a new $390.00 price target on by analysts at BMO Capital Markets. They now have a “buy” rating on the stock.
  • 11/8/2018 – Humana had its price target raised by analysts at Bank of America Corp from $400.00 to $415.00. They now have a “buy” rating on the stock.
  • 11/8/2018 – Humana had its price target raised by analysts at Jefferies Financial Group Inc from $388.00 to $410.00. They now have a “buy” rating on the stock.
  • 10/5/2018 – Humana was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Shares of Humana have outperformed its industry’s growth year to date. Moreover, the company has witnessed its 2019 earnings estimates move upward over the last seven days. The insurer is well-poised for growth on its strong Medicare business. Its top line has been witnessing an uptrend for the past several years. Sufficient generation of cash flow has helped the company take up many capital deployment initiatives aimed at enhancing its shareholder value. Humana’s sound balance sheet and a disciplined capital management remain its major tailwinds. Acquisitions and dispositions made by the company have also led to business growth over the last few quarters. Following the solid second-quarter results and the buyouts of Curo Healthcare and Kindred, the company provided a bullish EPS guidance for 2018. However, its rising level of expenses persistently weighs on the bottom line.”
  • 10/4/2018 – Humana was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $377.00 price target on the stock. According to Zacks, “Shares of Humana have outperformed its industry’s growth year to date. Moreover, the company has witnessed its 2019 earnings estimates move upward over the last seven days. The insurer is well-poised for growth on its strong Medicare business. Its top line has been witnessing an uptrend for the past several years. Sufficient generation of cash flow has helped the company take up many capital deployment initiatives aimed at enhancing its shareholder value. Humana’s sound balance sheet and a disciplined capital management remain its major tailwinds. Acquisitions and dispositions made by the company have also led to business growth over the last few quarters. Following the solid second-quarter results and the buyouts of Curo Healthcare and Kindred, the company provided a bullish EPS guidance for 2018. However, its rising level of expenses persistently weighs on the bottom line.”

Humana stock traded down $3.18 during midday trading on Tuesday, reaching $307.22. The company’s stock had a trading volume of 1,705,266 shares, compared to its average volume of 762,089. Humana Inc has a fifty-two week low of $233.82 and a fifty-two week high of $355.88. The company has a debt-to-equity ratio of 0.45, a quick ratio of 1.68 and a current ratio of 1.68. The company has a market cap of $43.86 billion, a P/E ratio of 26.24, a price-to-earnings-growth ratio of 1.52 and a beta of 1.03.

Humana (NYSE:HUM) last released its quarterly earnings results on Wednesday, November 7th. The insurance provider reported $4.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.29 by $0.29. The business had revenue of $14.21 billion during the quarter, compared to the consensus estimate of $13.97 billion. Humana had a return on equity of 19.10% and a net margin of 2.70%. During the same quarter in the previous year, the company posted $3.39 EPS. Sell-side analysts predict that Humana Inc will post 14.43 EPS for the current year.

The company also recently declared a quarterly dividend, which will be paid on Friday, January 25th. Stockholders of record on Monday, December 31st will be paid a dividend of $0.50 per share. This represents a $2.00 annualized dividend and a dividend yield of 0.65%. The ex-dividend date is Friday, December 28th. Humana’s dividend payout ratio (DPR) is presently 17.08%.

In related news, insider Roy A. Beveridge sold 4,622 shares of the business’s stock in a transaction dated Thursday, November 8th. The shares were sold at an average price of $341.06, for a total value of $1,576,379.32. Following the completion of the transaction, the insider now owns 10,621 shares of the company’s stock, valued at approximately $3,622,398.26. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Bruce D. Broussard sold 18,000 shares of the business’s stock in a transaction dated Monday, September 10th. The shares were sold at an average price of $328.66, for a total transaction of $5,915,880.00. Following the completion of the transaction, the chief executive officer now directly owns 71,085 shares of the company’s stock, valued at approximately $23,362,796.10. The disclosure for this sale can be found here. Insiders own 0.60% of the company’s stock.

A number of hedge funds have recently made changes to their positions in the stock. Capital International Investors grew its holdings in Humana by 3,030.3% in the 3rd quarter. Capital International Investors now owns 8,217,296 shares of the insurance provider’s stock valued at $2,781,719,000 after buying an additional 7,954,786 shares during the period. FMR LLC grew its holdings in Humana by 12.7% in the 2nd quarter. FMR LLC now owns 12,212,514 shares of the insurance provider’s stock valued at $3,634,811,000 after buying an additional 1,374,030 shares during the period. Renaissance Technologies LLC grew its holdings in Humana by 14.1% in the 3rd quarter. Renaissance Technologies LLC now owns 3,174,800 shares of the insurance provider’s stock valued at $1,074,733,000 after buying an additional 391,300 shares during the period. Glenmede Trust Co. NA grew its holdings in Humana by 153.7% in the 2nd quarter. Glenmede Trust Co. NA now owns 500,266 shares of the insurance provider’s stock valued at $148,895,000 after buying an additional 303,080 shares during the period. Finally, Ffcm LLC grew its holdings in Humana by 5,891.4% in the 3rd quarter. Ffcm LLC now owns 288,544 shares of the insurance provider’s stock valued at $14,968,000 after buying an additional 283,728 shares during the period. 93.05% of the stock is owned by hedge funds and other institutional investors.

Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. The company operates through four segments: Retail; Group and Specialty; Healthcare Services; and Individual Commercial. The Retail segment offers Medicare and supplemental benefit plans to individuals or through group accounts.

See Also: What is the Dividend Aristocrat Index?

Receive News & Ratings for Humana Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana Inc and related companies with MarketBeat.com's FREE daily email newsletter.